Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.40 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 2/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | FPR2 | P25090 | 1/20 | 0.36 |
| ▸ | SYNJ2 | O15056 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | STAT3 | P40763 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL851514 | 0.85 | PIK3CA (0.41) | CYP3A4MAPTPIK3CAMTORAURKA | |
| SCHEMBL19555271 | 0.81 | CYP3A4 (0.45) | CYP3A4MAPTMAOBALOX5PTGS2 | |
| SCHEMBL27200114 | 0.80 | RET (0.34) | CYP3A4MAPTMAOBALOX5PIK3CA | |
| SCHEMBL29066233 | 0.80 | DYRK1A (0.36) | CYP3A4MAPTMAOBALDH1A1SYNJ2 | |
| SCHEMBL23377569 | 0.78 | CYP3A4 (0.46) | CYP3A4MAPTMAOBALOX5PTGS2 | |
| SCHEMBL19555332 | 0.78 | CYP3A4 (0.37) | CYP3A4MAPTPIK3CASMPD3MTOR | |
| SCHEMBL30407910 | 0.78 | CYP3A4 (0.46) | CYP3A4MAPTMAOBALOX5PTGS2 | |
| SCHEMBL24316419 | 0.77 | PDGFRB (0.49) | MAPTMAOBPDGFRBPDGFRAALDH1A1 | |
| SCHEMBL16213730 | 0.77 | ALOX5 (0.48) | CYP3A4MAPTMAOBALOX5PTGS2 | |
| SCHEMBL365906 | 0.77 | MAPK1 (0.47) | CYP3A4MAPTPIK3CAAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118146056-A | Catalytic synthesis method of nitrogen-containing aromatic heterocyclic chlorinated organic compound | 河北威远生物化工有限公司 | 2024-06-07 | — | — | CN | disclosed |
| EP-3535243-B1 | SUBSTITUTED 9H-XANTHEN-9-ONE, 9H-THIOXANTHEN-9-ONE AND ACRIDIN-9(10H)-ONE DERIVATIVES AND RELATED COMPOUNDS CSF-1R INHIBITORS FOR THE TREATMENT OF CANCER | AUCKLAND UNISERVICES LTD (NZ) | 2021-12-15 | — | — | EP | disclosed |
| EP-3535243-B1 | SUBSTITUTED 9H-XANTHEN-9-ONE, 9H-THIOXANTHEN-9-ONE AND ACRIDIN-9(10H)-ONE DERIVATIVES AND RELATED COMPOUNDS CSF-1R INHIBITORS FOR THE TREATMENT OF CANCER | AUCKLAND UNISERVICES LTD (NZ) | 2021-12-15 | — | — | EP | disclosed |
| US-11028064-B2 | Tricyclic heterocyclic derivatives and uses thereof | AUCKLAND UNISERVICES LIMITED (NZ) | 2021-06-08 | — | — | US | disclosed |
| US-11028064-B2 | Tricyclic heterocyclic derivatives and uses thereof | AUCKLAND UNISERVICES LIMITED (NZ) | 2021-06-08 | — | — | US | disclosed |
| US-20190276423-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES AND USES THEREOF | AUCKLAND UNISERVICES LIMITED (NZ) | 2019-09-12 | — | — | US | disclosed |
| US-20190276423-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES AND USES THEREOF | AUCKLAND UNISERVICES LIMITED (NZ) | 2019-09-12 | — | — | US | disclosed |
| EP-3535243-A2 | TRICYCLIC HETEROCYCLIC DERIVATIVES AND USES THEREOF | Auckland Uniservices Limited (NZ) | 2019-09-11 | — | — | EP | disclosed |
| CN-110139852-A | Tricyclic heterocyclic derivatives and use thereof | 奥克兰联合服务有限公司 | 2019-08-16 | — | — | CN | disclosed |
| US-9296711-B2 | Substituted isoxazole amide compounds as inhibitors of stearoyl-CoA desaturase 1 (SCD1) | HOFFMAN-LA ROCHE INC. (US) | 2016-03-29 | — | — | US | disclosed |
| EP-2590944-A1 | 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | Actelion Pharmaceuticals Ltd. (CH) | 2013-05-15 | — | — | EP | disclosed |
| US-20130109685-A1 | 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-05-02 | — | — | US | disclosed |
| WO-2012004722-A1 | 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-01-12 | — | — | WO | disclosed |
| US-RE36256-E | ADMINISTERING ARYL-SUBSTITUTED QUINOXALINE DERIVATIVES AS ANTIPROLIFERATIVE, ANTICARCINOGENIC AND ANTITUMOR AGENTS | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1999-07-20 | — | — | US | disclosed |
| US-5795889-A | INHIBITING CELL GROWTH WITH ENZYME INHIBITORS FOR SKIN DISORDERS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-08-18 | — | — | US | disclosed |
| US-5656643-A | QUINOLIN PYRIDINE DERIVATIVES; USEFUL FOR TREATING CANCER, LEKEMIA, PSORIASIS, INFLAMMATORY DISODERS, BONE DISORDERS, ATHEROSCLEROSIS AND RESTENOSIS; CONTROLLS CELLULAR REPRODUCTION | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-08-12 | — | — | US | disclosed |
| US-5646153-A | INHIBITING ABNORMAL CELL PROLIFERATION | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-07-08 | — | — | US | disclosed |
| US-5480883-A | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1996-01-02 | — | — | US | disclosed |
| US-5409930-A | Inhibits abnoramal cell proliferation; dimethoxyquinoline/ dimethylquinoline/ quinolineoxide/ and quinoxaline derivatives | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1995-04-25 | — | — | US | disclosed |
| WO-1992020642-A1 | BIS MONO-AND BICYCLIC ARYL AND HETEROARYL COMPOUNDS WHICH INHIBIT EGF AND/OR PDGF RECEPTOR TYROSINE KINASE | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1992-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11028064-B2 | Tricyclic heterocyclic derivatives and uses thereof | CSF3R, CSF1R, FLT3 | CYP3A4 4407/4885MAPT 4017/4885MAOB 1269/4885 |
| US-20130109685-A1 | 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | PTGER1, PTGDR, PTGDR2 | CYP3A4 434/4885MAPT 4762/4885MAOB 711/4885 |
| US-20190276423-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES AND USES THEREOF | CSF3R, CSF1R, FLT3 | CYP3A4 4407/4885MAPT 4017/4885MAOB 1269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.